The test is the fourth assay on the firm's Revogene system and it detects five common genetic causes of drug resistance.
The firm is developing a multipanel test and an antibiotic resistance panel to augment its recently CE marked chlamydia and gonorrhea assay.
With DNA methylation data for more than 1,800 chronic lymphocytic leukemia B cells, researchers tracked CLL epimutation rates and saw lineages with distinct treatment responses.
The facility will be mass spec-focused and comprise a service contract lab for developing protein tests and a CAP- and CLIA-certified lab for offering them.
The company plans to use the funds to support further commercialization of its tumor tissue sequencing test, the Paradigm Cancer Diagnostic.
Researchers who go persevere after an early funding setback end up with more highly cited papers later on, according to the Economist.
In Genome Biology this week: archaic gene flow into sub-Saharan African populations, a de novo transcriptome assembler, and more.
The firm will use the proceeds to scale operations, advance its companion diagnostics program, and further expand its minimal residual disease program.
The company also reported a jump in its first quarter net loss as operating expenses climbed on higher research and development spending.
With $50 million from Japanese firm NEC, biomedical software startup BostonGene seeks to assess patients' "immune fitness" in the quest for better therapies.
Researchers tie a variant in ADAMTS3 to breathing difficulties in dissimilar dog breeds, according to Discover's D-brief blog.
Parents of children with rare genetic disease have to contend with shifts in the interpretation of genetic variants, the Wall Street Journal reports.
The Japan Times reports that researchers sequenced the genome of a woman who lived during the Jomon period.
In Science this week: single-nucleus RNA sequencing of brain tissue from individuals with autism, and more.